Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

被引：41
|
作者：
Doebele, R. [1 ]
Ahn, M. [2 ]
Siena, S. [3 ,4 ]
Drilon, A. [5 ]
Krebs, M. [6 ]
Lin, C. [7 ]
De Braud, F. [8 ]
John, T. [9 ]
Tan, D. [10 ]
Seto, T. [11 ]
Dziadziuszko, R. [12 ]
Arkenau, H. [13 ]
Barlesi, F. [14 ]
Rolfo, C. [15 ]
Wolf, J. [16 ]
Chow-Maneval, E. [17 ]
Multani, P. [17 ]
Cui, N. [18 ]
Riehl, T. [18 ]
Cho, B. C. [9 ]
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Div Hematol Oncol,Dept Med, Seoul, South Korea
[3] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Milan, Italy
[4] Univ Milan, Milan, Italy
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Div Solid Tumor Oncol, Thorac Oncol Serv, New York, NY 10021 USA
[6] Univ Manchester, Manchester, Lancs, England
[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[8] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[9] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea
[10] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore
[11] Natl Kyushu Canc Ctr, Dept Thorac Oncol, Fukuoka, Fukuoka, Japan
[12] Med Univ Gdansk, Dept Oncol & Radiotherapy, Gdansk, Poland
[13] Sarah Cannon Res Inst, London, England
[14] Aix Marseille Univ, AP HM, Marseille, France
[15] Antwerp Univ Hosp, Oncol Dept, Phase 1 Early Clin Trials Unit, Antwerp, Belgium
[16] Univ Hosp Cologne, Ctr Integrated Oncol Koln Bonn, Cologne, Germany
[17] Ignyta Inc, San Diego, CA USA
[18] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
NSCLC; entrectinib; ROS1 gene fusion;
D O I：
10.1016/j.jtho.2018.08.239
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA02.01
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [1] Entrectinib in Patients with Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
    Ahn, M.
    Cho, B. C.
    Siena, S.
    Drilon, A.
    De Braud, F.
    Krebs, M.
    John, T.
    Karapetis, C.
    Johnson, A.
    Chow-Maneval, E.
    Multani, P.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1783 - S1783
  • [2] Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC
    Drilon, Alexander
    Chiu, Chao-Hua
    Fan, Yun
    Cho, Byoung Chul
    Lu, Shun
    Ahn, Myung-Ju
    Krebs, Matthew G.
    Liu, Stephen, V
    John, Thomas
    Otterson, Gregory A.
    Tan, Daniel S. W.
    Patil, Tejas
    Dziadziuszko, Rafal
    Massarelli, Erminia
    Seto, Takashi
    Doebele, Robert C.
    Pitcher, Bethany
    Kurtsikidze, Nino
    Heinzmann, Sebastian
    Siena, Salvatore
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 3 (06):
  • [3] Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
    Fan, Yun
    Drilon, Alexander
    Chiu, Chao-Hua
    Loong, Herbert H. F.
    Siena, Salvatore
    Krzakowski, Maciej
    Dziadziuszko, Rafal
    Zeuner, Harald
    Xue, Cloris
    Krebs, Matthew G.
    CLINICAL LUNG CANCER, 2024, 25 (02) : e81 - e86.e4
  • [4] Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer
    Cho, Byoung Chul
    Chiu, Chao-Hua
    Massarelli, Erminia
    Buchschacher, Gary L.
    Goto, Koichi
    Overbeck, Tobias R.
    Loong, Herbert H. F.
    Chee, Cheng E.
    Garrido, Pilar
    Dong, Xiaorong
    Fan, Yun
    Lu, Shun
    Schwemmers, Sven
    Bordogna, Walter
    Zeuner, Harald
    Osborne, Stuart
    John, Thomas
    LUNG CANCER, 2024, 188
  • [5] Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis
    Fan, Y.
    Drilon, A.
    Chiu, C. -H.
    Bowles, D. W.
    Loong, H. H. F.
    Siena, S.
    Goto, K.
    Krzakowski, M.
    Ahn, M. -J.
    Murakami, H.
    Dziadziuszko, R.
    Zeuner, H.
    Pitcher, B.
    Cheick, D.
    Krebs, M. G.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S89 - S90
  • [6] Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer
    Chu, Paula
    Antoniou, Miranta
    Bhutani, Mohit K.
    Aziez, Amine
    Daigl, Monica
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2020, 9 (12) : 861 - 876
  • [7] Entrectinib as first-line vs. second-line therapy in ROS1 fusion-positive non-small cell lung cancer: a cost-effectiveness analysis
    Huo, Gengwei
    Song, Ying
    Chen, Xiongwen
    Chen, Peng
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (04) : 839 - 848
  • [8] Advances and future directions in ROS1 fusion-positive lung cancer
    Boulanger, Mary C.
    Schneider, Jaime L.
    Lin, Jessica J.
    ONCOLOGIST, 2024, 29 (11): : 943 - 956
  • [9] Unusual presentation of ROS1 rearranged metastatic non-small cell lung cancer
    Chen, Lanyi Nora
    Keating, Claire
    Leb, Jay
    Saqi, Anjali
    Shu, Catherine A.
    RESPIRATORY MEDICINE CASE REPORTS, 2024, 51
  • [10] Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
    Paz-Ares, L.
    Barlesi, F.
    Siena, S.
    Ahn, M-J
    Drilon, A.
    Conley, A.
    Rolfo, C.
    Wolf, J.
    Seto, T.
    Doebele, R.
    Kapre, A.
    Chen, D.
    McCallum, S.
    Osborne, S.
    Demetri, G.
    ESMO OPEN, 2021, 6 (03)
12345